Navigation Links
Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus

-LymphoStat-B(R) significantly reduced signs and symptoms of SLE disease at 52 Weeks and demonstrated durable clinical and biological activity at 76 weeks-

ROCKVILLE, Md., June 14, 2007 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. today announced the presentation of Phase 2 trial data demonstrating that LymphoStat-B(R) (belimumab) significantly reduced disease activity across multiple clinical measures, was well tolerated and improved quality of life in patients with active systemic lupus erythematosus (SLE). The 52-week and 76-week results of the Phase 2 study were the subject of an oral presentation today in Barcelona at the annual congress of the European League Against Rheumatism (EULAR).

"A number of clinical measures used in the Phase 2 study demonstrate that LymphoStat-B produced significant improvements in disease activity in patients with serologically active SLE," said Ellen Ginzler, M.D., Professor of Medicine and Chief of Rheumatology at the Downstate Medical Center, State University of New York (SUNY) in Brooklyn. "At Week 52, we saw significant reductions in SLE disease activity as measured by the SELENA SLEDAI and BILAG indices and the Physician's Global Assessment, as well as the patient response rate chosen as the primary efficacy endpoint of the Phase 3 trials. Continued improvements were observed from Week 52 through Week 76 in the 24-week extension phase of the trial."

Dr. Ginzler noted that reductions observed in activated B cells and anti- dsDNA autoantibodies, as well as the improvements observed in health-related quality of life, were associated with therapeutic response. No increase in infections or infectious events was observed over time. "We look forward to continuing the evaluation of LymphoStat-B as a potential treatment for SLE in the Phase 3 trials that are now underway," she said.

Of the patients who completed 52 weeks of treatment in this randomize
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Testing for Human Papillomavirus
2. Bio-Matrix Scientifics Dr. ONeill Sees University of Pittsburghs Published Study on Culture Blood-Forming Stem Cells from Human Fat Tissue as Supporting Near Term Benefits of Banking Adipose (Fat) Derived Stem Cells
3. Phase II Results Show Once-Daily Dosing of Human GLP-1 Analog Liraglutide, Brings Patients to A1c Target
4. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
5. Modigene Announces Successful Completion of Pharmacokinetic & Pharmacodynamic Pre-Clinical Experiments for Proprietary Long-Acting Human Growth Hormone, Long-acting Interferon Beta and Long-acting Erythropoietin
6. Second Successful Quigley QR-443 Study Suggests Method of Action Relevant to Broad Range of Chronic Inflammatory Diseases - Human Study to Follow -
7. Research Documents Scalable Production, Survival Following Engraftment and Positive Impact on Cardiac Function in Infarcted Rats for Gerons Human Embryonic Stem Cell-Based Therapeutic for Heart Failure
8. NCI Researchers Discover Genes That Are Turned on at High Levels in Tumor-associated Blood Vessels of Mice and Humans
9. Research Indicates Gerons Human Embryonic Stem Cell-Based Therapeutic for Spinal Cord Injury Evades Direct Attack by the Human Immune System
10. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
11. Human Genome Sciences Announces Positive Final Results Of Phase 2b Trial of Albuferon
Post Your Comments:
(Date:5/23/2013)... Medical Systems, Inc. (NASDAQ: CASM ) (CASMED), a ... that Thomas M. Patton , President and ... Annual Marcum MicroCap Conference on Thursday, May 30, 2013, at ... . The presentation is scheduled to begin ... will be available via a live webcast at http://wsw.com/webcast/marcum/casm/ ...
(Date:5/23/2013)... , May 23, 2013 Halozyme Therapeutics, ... the appointment of David A. Ramsay ... was most recently Vice President, Corporate Development at ... "With his established financial management experience ... by working in our commercial group for the ...
(Date:5/23/2013)... EarlySense, the market leader in ... for ,Best Novel Idea, at the 8 th ... Conference, hosted this year in the UK by the ... research team studying the impact of the EarlySense contact-free ... Los Angeles . The prize was awarded for ...
Breaking Medicine Technology:CASMED to Present at the 2nd Annual Marcum MicroCap Conference 2Halozyme Therapeutics Names David A. Ramsay Chief Financial Officer 2Clinical Team Researching the Impact of the EarlySense System Wins 'Best Novel Idea' Prize at the Rapid Response Systems and Medical Emergency Teams 2013 8th International Conference 2Clinical Team Researching the Impact of the EarlySense System Wins 'Best Novel Idea' Prize at the Rapid Response Systems and Medical Emergency Teams 2013 8th International Conference 3Clinical Team Researching the Impact of the EarlySense System Wins 'Best Novel Idea' Prize at the Rapid Response Systems and Medical Emergency Teams 2013 8th International Conference 4
... Capital, Inc. announced the initial closing of a private ... A total of 500,000 Units, each Unit consisting of ... purchase warrants, were sold, generating gross proceeds of approximately ... working capital and research and development related to Arrogene,s ...
... Conn., Jan. 19, 2012  The Specialty Photonics Division ... provider of optical fiber, cable, and assemblies for ... will present "Optical fibers with polyimide coatings for ... Dr. Stolov will present on Sunday, January 22nd ...
Cached Medicine Technology:WestPark Capital, Inc. Announces $500,000 Arrogene NanoTechnology, Inc. Offering 2OFS to Present Paper on Optical Fibers with Polyimide Coatings for Medical Applications 2
(Date:5/24/2013)... (PRWEB) May 24, 2013 Patients who ... more likely to suffer from gastroesophageal reflux disease or ... reported in a study published today. , The article, ... Proximal Exposure as Measured by Hypopharyngeal Multichannel Intraluminal Impedance” ... could be of great importance to individuals who live ...
(Date:5/24/2013)... May 24, 2013 For the second ... Braeda Fresh Express Café to treat Tabitha Meals on ... to their door. More than 400 meal recipients recently ... the restaurants, along with the rest of a well-balanced, ... proud to partner with the Tabitha Meals on Wheels ...
(Date:5/24/2013)... With today’s levels of weight gain and ... on the causes of weight gain and how to lose ... causes of weight gain and treatments that will help patients ... released by the Child Study Center at NYU Langone Medical ... of ADHD and the soring rates of obesity later in ...
(Date:5/24/2013)... Today marks the launch of Destination Halifax’s ... , The redesigned and enhanced Itinerary Builder will help ... their computer or mobile device that they can send, ... users to fill in their date of arrival and ... choice of vacation packages, accommodations, restaurants, and things to ...
(Date:5/24/2013)... May 24, 2013 http://www.resource4thepeople.com/defectivedrugs/Zithromax-lawsuits.html ... the latest update involving allegations that the use ... (azithromycin) can allegedly cause potentially fatal irregular ... on May 17, 2013* that Health Canada has ... warning that Zithromax can cause abnormal changes in ...
Breaking Medicine News(10 mins):Health News:West Penn Allegheny Health System Physicians Pinpoint Gastroesophageal Reflux Disease (GERD) as a Factor That May Cause Chronic Cough 2Health News:Runza® Delivers Sandwiches, Draws Smiles from Tabitha Meals on Wheels Clients 2Health News:hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Now Help Patients with Weight Gain Linked to Childhood ADHD Lose Weight Fast 2Health News:Create and Win the Perfect Halifax Getaway with the All-New Itinerary Builder 2Health News:2013 Alleged Zithromax Arrhythmia and Sudden Death Cases Update: Canadian Health Officials Issue Warning 2Health News:2013 Alleged Zithromax Arrhythmia and Sudden Death Cases Update: Canadian Health Officials Issue Warning 3Health News:2013 Alleged Zithromax Arrhythmia and Sudden Death Cases Update: Canadian Health Officials Issue Warning 4
... has been approved by the U.S. Food and Drug Administration (FDA) ... regimen to treat moderate to severe postmenopausal dyspareunia (painful sexual intercourse) ... ... COLLEGEVILLE, Pa. (Business Wire EON) November 13, 2008 -- ...
... of nest eggs, homes or jobs, their young children ... Michele C. Thorne, Ph.D., assistant professor of clinical psychology ... director of the Consult Liaison Service at Riley Hospital ... newborn babies pick up on the emotional tones of ...
... 13 SuperGen, Inc.,(Nasdaq: SUPG ), a ... novel cancer therapies, today announced that James S.,Manuso, ... to,present at the Lazard Capital Markets Fifth Annual ... St. Regis in New York, New York., ...
... Nov. 13 Dowden Health Media,s,beginnings were reflected in ... number 1 of the Dowden Dispatch an employee newsletter,which ... According to Mark Dowden, one of the founders ... one morning in 1988, as he stood,in his parents, ...
... providers join forces to provide superior customer care, ... Multi Vendor,Service announced today that it will form ... respected leaders in the ultrasound transducer repair,industry., ... brings together two of the most reputable,high-quality service ...
... seem to know exactly what types of cells to ... will inexplicably spare a seemingly identical group of neighbors. ... the kinds and amounts of proteins they produce - ... For this reason, scientists have struggled to parse the ...
Cached Medicine News:Health News: FDA Approves Low-dose Regimen of PREMARIN Vaginal Cream to Treat Moderate to Severe Postmenopausal Dyspareunia – Painful Sexual Intercourse : Agency Grants New Indication for Bothersome Vaginal Symptom Associated with Menopause 2Health News: FDA Approves Low-dose Regimen of PREMARIN Vaginal Cream to Treat Moderate to Severe Postmenopausal Dyspareunia – Painful Sexual Intercourse : Agency Grants New Indication for Bothersome Vaginal Symptom Associated with Menopause 3Health News: FDA Approves Low-dose Regimen of PREMARIN Vaginal Cream to Treat Moderate to Severe Postmenopausal Dyspareunia – Painful Sexual Intercourse : Agency Grants New Indication for Bothersome Vaginal Symptom Associated with Menopause 4Health News:Helping children and teens deal with stress in an uncertain time 2Health News:Dowden Health Media: 20 Years and Growing 2Health News:MEDRAD Multi Vendor Service Forms Alliance with Wetsco 2Health News:MEDRAD Multi Vendor Service Forms Alliance with Wetsco 3Health News:Breakthrough in cell-type analysis offers new ways to study development and disease 2Health News:Breakthrough in cell-type analysis offers new ways to study development and disease 3Health News:Breakthrough in cell-type analysis offers new ways to study development and disease 4
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: